230 related articles for article (PubMed ID: 35351523)
1. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion.
Wong AM; Ding X; Wong AM; Xu M; Zhang L; Leung HH; Chan AW; Song QX; Kwong J; Chan LK; Man M; He M; Chen J; Zhang Z; You W; Lau C; Yu A; Wei Y; Yuan Y; Lai PB; Zhao J; Man K; Yu J; Kahn M; Wong N
J Hepatol; 2022 Aug; 77(2):410-423. PubMed ID: 35351523
[TBL] [Abstract][Full Text] [Related]
2. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
4. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
5. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
7. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
Ando S; Shibahara J; Hayashi A; Fukayama M
Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation.
Ding X; Yang Y; Han B; Du C; Xu N; Huang H; Cai T; Zhang A; Han ZG; Zhou W; Chen L
PLoS One; 2014; 9(5):e95307. PubMed ID: 24798046
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
10. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
Akasu M; Shimada S; Kabashima A; Akiyama Y; Shimokawa M; Akahoshi K; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Sci Rep; 2021 Aug; 11(1):16732. PubMed ID: 34429454
[TBL] [Abstract][Full Text] [Related]
12. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
13. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Ruiz de Galarreta M; Bresnahan E; Molina-Sánchez P; Lindblad KE; Maier B; Sia D; Puigvehi M; Miguela V; Casanova-Acebes M; Dhainaut M; Villacorta-Martin C; Singhi AD; Moghe A; von Felden J; Tal Grinspan L; Wang S; Kamphorst AO; Monga SP; Brown BD; Villanueva A; Llovet JM; Merad M; Lujambio A
Cancer Discov; 2019 Aug; 9(8):1124-1141. PubMed ID: 31186238
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
[TBL] [Abstract][Full Text] [Related]
15. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
[TBL] [Abstract][Full Text] [Related]
17. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
[TBL] [Abstract][Full Text] [Related]
18. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
[TBL] [Abstract][Full Text] [Related]
19. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
20. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]